Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing

Simple item page
dc.contributor.authorBirdwell, Kelly A.
dc.contributor.authorDecker, Brian
dc.contributor.authorBarbarino, Julia M.
dc.contributor.authorPeterson, Josh F.
dc.contributor.authorStein, C. Michael
dc.contributor.authorSadee, Wolfgang
dc.contributor.authorWang, Danxin
dc.contributor.authorVinks, Alexander A.
dc.contributor.authorHe, Yijing
dc.contributor.authorSwen, Jesse J.
dc.contributor.authorLeeder, J. Steven
dc.contributor.authorvan Schaik, RHN
dc.contributor.authorThummel, Kenneth E.
dc.contributor.authorKlein, Teri E.
dc.contributor.authorCaudle, Kelly E.
dc.contributor.authorMacPhee, Iain A.M.
dc.contributor.departmentDepartment of Medicine, IU School of Medicineen_US
dc.date.accessioned2015-11-13T20:31:54Z
dc.date.available2015-11-13T20:31:54Z
dc.date.issued2015-07
dc.description.abstractTacrolimus is the mainstay immunosuppressant drug used after solid organ and hematopoietic stem cell transplantation. Individuals who express CYP3A5 (extensive and intermediate metabolizers) generally have decreased dose-adjusted trough concentrations of tacrolimus as compared with those who are CYP3A5 nonexpressers (poor metabolizers), possibly delaying achievement of target blood concentrations. We summarize evidence from the published literature supporting this association and provide dosing recommendations for tacrolimus based on CYP3A5 genotype when known (updates at www.pharmgkb.org).en_US
dc.eprint.versionAuthor's manuscripten_US
dc.identifier.citationBirdwell, K. A., Decker, B., Barbarino, J. M., Peterson, J. F., Stein, C. M., Sadee, W., … MacPhee, I. A. M. (2015). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. Clinical Pharmacology and Therapeutics, 98(1), 19–24. http://doi.org/10.1002/cpt.113en_US
dc.identifier.urihttps://hdl.handle.net/1805/7451
dc.language.isoen_USen_US
dc.publisherWileyen_US
dc.relation.isversionof10.1002/cpt.113en_US
dc.relation.journalClinical Pharmacology and Therapeuticsen_US
dc.rightsIUPUI Open Access Policyen_US
dc.sourcePMCen_US
dc.subjectTacrolimusen_US
dc.subjectCYP3A5en_US
dc.subjectImmunosuppressanten_US
dc.subjectPharmacogeneticsen_US
dc.subjectPharmacogenomicsen_US
dc.subjectTransplanten_US
dc.titleClinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosingen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
nihms670362.pdf
Size:
70.64 KB
Format:
Adobe Portable Document Format
Description:
Main Article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.88 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Policy Articles
Department of Medicine Works